Generic Minolira Availability
Minolira is a brand name of minocycline, approved by the FDA in the following formulation(s):
MINOLIRA (minocycline hydrochloride - tablet, extended release;oral)
-
Manufacturer: DR REDDYS LABS LTD
Approval date: May 8, 2017
Strength(s): EQ 105MG BASE, EQ 135MG BASE
Has a generic version of Minolira been approved?
No. There is currently no therapeutically equivalent version of Minolira available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minolira. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Minolira (minocycline)
- Minolira Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Drug class: tetracyclines
Consumer resources
Other brands: Minocin, Solodyn, Dynacin, Ximino, ... +2 more
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
